lower respiratory system in humans along with other creatures. SARS-CoV-2 is really a lately emerged coronavirus which has brought to some global pandemic creating a severe respiratory system disease referred to as COVID-19 with significant morbidity and mortality worldwide. The introduction of antiviral therapeutics are urgently needed while vaccine programs unveil worldwide. Ideas describe a diamidobenzimidazole compound, diABZI-4, that activates STING and it is impressive in restricting SARS-CoV-2 replication in cells and creatures. diABZI-4 inhibited SARS-CoV-2 replication in lung epithelial cells. Administration of diABZI-4 intranasally before or perhaps after virus infection conferred complete defense against severe respiratory system disease in K18-ACE2-transgenic rodents have contracted SARS-CoV-2. Intranasal delivery of diABZI-4 caused an immediate short-resided activation of STING, resulting in transient proinflammatory cytokine production and lymphocyte activation within the lung connected with inhibition of viral replication. Our study supports using diABZI-4 like a host-directed therapy which mobilizes antiviral defenses for that prevention and treatment of COVID-19.